SC-26196 | CAS#218136-59-5 | D6D inhibitor

MedKoo Cat#: 555802 | Name: SC-26196

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SC-26196 is a D6D inhibitor (IC50 = 0.2 µM in a rat liver microsomal assay) that completely blocks the conversion of linoleic acid to arachidonic acid (AA). SC-26196 inhibited the desaturation of 2 microM [1-14C] 18:2n-6 by 87-95% in cultured human skin fibroblasts, coronary artery smooth muscle cells, and astrocytes. By contrast, SC-26196 did not affect the conversion of [1-14C]20:3n-6 to 20:4 in the fibroblasts, demonstrating that it is selective for delta6-desaturase.

Chemical Structure

SC-26196

CAS#218136-59-5

Theoretical Analysis

MedKoo Cat#: 555802

Name: SC-26196

CAS#: 218136-59-5

Chemical Formula: C27H29N5

Exact Mass: 423.2423

Molecular Weight: 423.56

Elemental Analysis: C, 76.56; H, 6.90; N, 16.53

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship
500mg	USD 2,650.00	Ready to ship
1g	USD 3,850.00	Ready to ship
2g	USD 6,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SC-26196; SC 26196; SC26196;

IUPAC/Chemical Name

(E)-2,2-diphenyl-5-(4-((pyridin-3-ylmethylene)amino)piperazin-1-yl)pentanenitrile

InChi Key

QFYKXKMYVYOUNJ-JBASAIQMSA-N

InChi Code

QFYKXKMYVYOUNJ-JBASAIQMSA-N

SMILES Code

N#CC(C1=CC=CC=C1)(C2=CC=CC=C2)CCCN3CCN(/N=C/C4=CN=CC=C4)CC3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A20T09K02

QC Data

View QC data: current batch, Lot#A20T09K02

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

SC-26196 is a potent, orally active Delta6 desaturase (D6D, FADS2) inhibitor (IC50=0.2 µM in a rat liver microsomal assay).

In vitro activity:

SC-26196 significantly reduced the desaturation of specific fatty acids (18:2n-6, 18:3n-3, 24:5n-3) by 87-95% in various human cell types. SC-26196 selectively targeted delta6-desaturase without affecting other pathways. SC-26196 inhibited the conversion of certain fatty acids to DHA by 75-84%. Reference: Lipids. 2003 Apr;38(4):469-76. https://pubmed.ncbi.nlm.nih.gov/12848296/

In vivo activity:

In two in vivo models of intestinal cancer, SC-26196 treatment resulted in 36-37% fewer tumors in Apc(Min/+) mice and 35% decrease in primary tumor size in nude mice bearing HT-29 human colon cancer cell xenografts (P<0.05). SC-26196 treatment resulted in significantly higher linoleic acid levels in tissue phospholipids and lower levels of arachidonic acid. Reference: Cancer Lett. 2002 Jan 25;175(2):157-63. https://pubmed.ncbi.nlm.nih.gov/11741743/

	Solvent	mg/mL	mM
Solubility
	DMSO	10.0	23.60

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 423.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wang C, MacIntyre B, Mutch DM. Inhibition of Δ-6 desaturase reduces fatty acid re-esterification in 3T3-L1 adipocytes independent of changes in n3-PUFA cellular content. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jul;1867(7):159160. doi: 10.1016/j.bbalip.2022.159160. Epub 2022 Apr 11. PMID: 35421603. 2. Harmon SD, Kaduce TL, Manuel TD, Spector AA. Effect of the delta6-desaturase inhibitor SC-26196 on PUFA metabolism in human cells. Lipids. 2003 Apr;38(4):469-76. doi: 10.1007/s11745-003-1086-9. PMID: 12848296. 3. Wang J, Liang H, Sun M, Zhang L, Xu H, Liu W, Li Y, Zhou Y, Li Y, Li M. Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo. Cancer Manag Res. 2018 Dec 7;10:6779-6790. doi: 10.2147/CMAR.S185601. PMID: 30584371; PMCID: PMC6289123. 4. Hansen-Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Masferrer J, Zweifel B, Chiu CH, Whelan J. Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis. Cancer Lett. 2002 Jan 25;175(2):157-63. doi: 10.1016/s0304-3835(01)00715-7. PMID: 11741743.

In vitro protocol:

In vivo protocol:

1. Wang J, Liang H, Sun M, Zhang L, Xu H, Liu W, Li Y, Zhou Y, Li Y, Li M. Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo. Cancer Manag Res. 2018 Dec 7;10:6779-6790. doi: 10.2147/CMAR.S185601. PMID: 30584371; PMCID: PMC6289123. 2. Hansen-Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Masferrer J, Zweifel B, Chiu CH, Whelan J. Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis. Cancer Lett. 2002 Jan 25;175(2):157-63. doi: 10.1016/s0304-3835(01)00715-7. PMID: 11741743.

1: Obukowicz MG, Welsch DJ, Salsgiver WJ, Martin-Berger CL, Chinn KS, Duffin KL, Raz A, Needleman P. Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. J Pharmacol Exp Ther. 1998 Oct;287(1):157-66. PMID: 9765335. 2: Obukowicz M, Welsch D, Salsgiver W, Martin-Berger C, Chinn K, Duffin K, Raz A, Needleman P. Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. Lipids. 1999;34 Suppl:S149. doi: 10.1007/BF02562269. PMID: 10419129. 3: Hansen-Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Masferrer J, Zweifel B, Chiu CH, Whelan J. Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis. Cancer Lett. 2002 Jan 25;175(2):157-63. doi: 10.1016/s0304-3835(01)00715-7. PMID: 11741743. 4: Duffin KL, Obukowicz MG, Salsgiver WJ, Welsch DJ, Shieh C, Raz A, Needleman P. Lipid remodeling in mouse liver and plasma resulting from delta6 fatty acid desaturase inhibition. Lipids. 2001 Nov;36(11):1203-8. doi: 10.1007/s11745-001-0833-2. PMID: 11795852. 5: Harmon SD, Kaduce TL, Manuel TD, Spector AA. Effect of the delta6-desaturase inhibitor SC-26196 on PUFA metabolism in human cells. Lipids. 2003 Apr;38(4):469-76. doi: 10.1007/s11745-003-1086-9. PMID: 12848296. 6: Hargrave-Barnes KM, Azain MJ, Miner JL. Conjugated linoleic acid-induced fat loss dependence on Delta6-desaturase or cyclooxygenase. Obesity (Silver Spring). 2008 Oct;16(10):2245-52. doi: 10.1038/oby.2008.338. Epub 2008 Jul 24. PMID: 18719641. 7: Zhang L, Ramtohul Y, Gagné S, Styhler A, Wang H, Guay J, Huang Z. A multiplexed cell assay in HepG2 cells for the identification of delta-5, delta-6, and delta-9 desaturase and elongase inhibitors. J Biomol Screen. 2010 Feb;15(2):169-76. doi: 10.1177/1087057109356208. Epub 2010 Jan 19. PMID: 20086206. 8: Mulligan CM, Le CH, deMooy AB, Nelson CB, Chicco AJ. Inhibition of delta-6 desaturase reverses cardiolipin remodeling and prevents contractile dysfunction in the aged mouse heart without altering mitochondrial respiratory function. J Gerontol A Biol Sci Med Sci. 2014 Jul;69(7):799-809. doi: 10.1093/gerona/glt209. Epub 2014 Jan 13. PMID: 24418793; PMCID: PMC4111632. 9: Sibbons CM, Irvine NA, Pérez-Mojica JE, Calder PC, Lillycrop KA, Fielding BA, Burdge GC. Polyunsaturated Fatty Acid Biosynthesis Involving Δ8 Desaturation and Differential DNA Methylation of FADS2 Regulates Proliferation of Human Peripheral Blood Mononuclear Cells. Front Immunol. 2018 Mar 5;9:432. doi: 10.3389/fimmu.2018.00432. PMID: 29556240; PMCID: PMC5844933. 10: Wang J, Liang H, Sun M, Zhang L, Xu H, Liu W, Li Y, Zhou Y, Li Y, Li M. Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo. Cancer Manag Res. 2018 Dec 7;10:6779-6790. doi: 10.2147/CMAR.S185601. PMID: 30584371; PMCID: PMC6289123. 11: Jeitany M, Prabhu A, Dakle P, Pathak E, Madan V, Kanojia D, Mukundan V, Jiang YY, Landesman Y, Tam WL, Kappei D, Koeffler HP. Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas. Cell Mol Life Sci. 2021 Feb;78(4):1837-1851. doi: 10.1007/s00018-020-03620-w. Epub 2020 Aug 26. PMID: 32851475; PMCID: PMC7904719. 12: Wang C, MacIntyre B, Mutch DM. Inhibition of Δ-6 desaturase reduces fatty acid re-esterification in 3T3-L1 adipocytes independent of changes in n3-PUFA cellular content. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jul;1867(7):159160. doi: 10.1016/j.bbalip.2022.159160. Epub 2022 Apr 11. PMID: 35421603.